Elevated production of interleukin-18 is associated with renal disease in patients with systemic lupus erythematosus

Clinical and Experimental Immunology

Volumn 130, Issue 2, 2002, Pages 345-351

  Wong, C K ^a   Ho, C Y ^a   Li, E K ^a   Tam, L S ^a   Lam, C W K ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Interleukin 18; Interleukin 18 receptor; Nitric oxide; Peripheral blood mononuclear cells; Systemic lupus erythematosus

Indexed keywords

INTERLEUKIN 18; INTERLEUKIN 18 RECEPTOR; MITOGENIC AGENT; NITRIC OXIDE;

ADULT; AGED; ARTICLE; COLORIMETRY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; CELLS, CULTURED; FEMALE; HUMANS; INTERLEUKIN-18; INTERLEUKIN-18 RECEPTOR ALPHA SUBUNIT; LEUKOCYTES, MONONUCLEAR; LUPUS NEPHRITIS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NITRIC OXIDE; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-18; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UP-REGULATION;

EID: 0036408785     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2002.01989.x     Document Type: Article

References (43)

1. Amital H, Shoenfeld Y. Autoimmunity and autoimmune diseases such as systemic lupus erythematosus. In: Lahita RG, ed. Systemic Lupus Erythematosus, 3rd Edn. London: Academic Press, 1999:1-11.
2. Kelley VR, Wuthrich RP. Cytokines in the pathogenesis of systemic lupus erythematosus. Semin Nephrol 1999; 19:57-66.
3. Kaneko H, Ogasawara H, Naito T et al. Circulating levels of beta-chemokines in systemic lupus erythematosus. J Rheumatol 1999; 26:568-73.
4. Perez de Lema G, Maier H, Nieto E et al. Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J Am Soc Nephrol 2001; 12:1369-82.
5. H1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 1999; 103:11-24.
6. Torigoe K, Ushio S, Okura T et al. Purification and characterization of the human interleukin-18 receptor. J Biol Chem 1997; 272:25737-42.
7. Xu D, Chan WL, Leung BP et al. Selective expression and functions of interleukin 18 receptor on T helper (Th) type 1 but not Th2 cells. J Exp Med 1998; 188:1485-92.
8. + human blood mononuclear cells. J Clin Invest 1998; 101:711-21.
9. Tanaka M, Harigai M, Kawaguchi Y et al. Mature form of interleukin 18 is expressed in rheumatoid arthritis synovial tissue and contributes to interferon-gamma production by synovial T cells. J Rheumatol 2001; 28:1779-87.
10. Wang W, Tanaka T, Okamura H et al. Interleukin-18 enhances the production of interleukin-8 by eosinophils. Eur J Immunol 2001; 31:1010-6.
11. Dao T, Ohashi K, Kayano T, Kurimoto M, Okamura H. Interferon γ-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper cells. Cell Immunol 1996; 173:230-5.
12. Matsumoto K, Kanmatsuse K. Elevated interleukin-18 levels in the urine of nephrotic patients. Nephron 2001; 88:334-9.
13. Nicoletti F, Di Marco R, Mangano K et al. Increased serum levels of interleukin-18 in patients with multiple sclerosis. Neurology 2001; 57:342-4.
14. Kawaguchi Y, Terajima H, Harigai M, Hara M, Kamatani N. Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still's disease. Arthritis Rheum 2001; 44:1716-7.
15. Nicoletti F, Conget I, Di Marco R et al. Serum levels of the interferon-gamma-inducing cytokine interleukin-18 are increased in individuals at high risk of developing type I diabetes. Diabetologia 2001; 44:309-11.
16. Harandi AM, Svennerholm B, Holmgren J, Eriksson K. Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of acquired gamma interferon-mediated protective immunity. J Virol 2001; 75:6705-9.
17. Pirhonen J. Regulation of IL-18 expression in virus infection. Scand J Immunol 2001; 53:533-9.
18. Elsner J, Hochstetter R, Kimmig D, Kapp A. Human eotaxin represents a potent activator of the respiratory burst of human eosinophils. Eur J Immunol 1996; 26:1919-25.
19. Wong CK, Ho CY, Ko FWS et al. Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-γ, IL-4, IL-10 and IL-13) in patients with allergic asthma. Clin Exp Immunol 2001; 125:177-83.
20. McInnes IB, Gracie JA, Liew FY. Interleukin-18: A novel cytokine in inflammatory rheumatic disease. Arthritis Rheum 2001; 44:1481-3.
21. Wong CK, Li EK, Ho CY, Lam CWK. Elevation of plasma interleukin-18 concentration is correlated with disease activity in systemic lupus erythematosus. Rheumatol 2000; 39:1078-81.
22. Wong CK, Ho CY, Li EK, Lam CWK. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000; 9:589-93.
23. Weinberg JB, Granger DL, Pisetsky DS et al. The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: Increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine. J Exp Med 1994; 179:651-60.
24. Liu TF, Jones BM. Impaired production of IL-12 in systemic lupus erythematosus. II. IL-12 production in vitro is correlated negatively with serum IL-10, positively with serum IFN-γ and negatively with disease activity in SLE. Cytokines 1998; 10:148-53.
25. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271-7.
26. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. The Committee on Prognosis studies in SLE. Derivation of the SLEDAI: A disease activity index for lupus patients. Arthritis Rheum 1992; 35:630-40.
27. Viallard JF, Pellegrin JL, Ranchin V et al. Th1 (IL-2, interferon-gamma (IFN-gamma) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1999; 115:189-95.
28. Moller B, Kukoc-Zivojnov N, Kessler U et al. Expression of interleukin-18 and its monokine-directed function in rheumatoid arthritis. Rheumatol 2001; 40:302-9.
29. Wong CK, Ho CY, Lam CW, Zhang JP, Hjelm NM. Differentiation of a human eosinophilic leukemic cell line, EoL-1: Characterization by the expression of cytokine receptors, adhesion molecules, CD95 and eosinophilic cationic protein (ECP). Immunol Lett 1999; 68:317-23.
30. Mohan C, Adams S, Stanik V, Datta SK. Nucleosome: A major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med 1993; 177:1367-81.
31. Tokano Y, Morimoto S, Kaneko H et al. Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE) - Relation to Th1-and Th2-derived cytokines. Clin Exp Immunol 1999; 116:169-73.
32. Davas EM, Tsirogianni A, Kappou I et al. Serum IL-6, TNF alpha, p55 srTNF alpha, p75 srTNF alpha, srIL-12 alpha levels and disease activity in systemic lupus erythematosus. Clin Rheumatol 1999; 18:17-22.
33. Al-Janadi M, Al-Balla S, Al-Dalaan A, Raziuddin S. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis and other rheumatic disease. J Clin Immunol 1993; 13:58-67.
34. Esfandiari E, McInnes IB, Lindop G et al. A proinflammatory role of IL-18 in the development of spontaneous autoimmune disease. J Immunol 2001; 167:5338-47.
35. Masutani K, Akahoshi M, Tsuruya K et al. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum 2001; 44:2097-106.
36. Neumann D, Del Giudice E, Ciaramella A, Boraschi D, Bossu P. Lymphocytes from autoimmune MRL lpr/lpr mice are hyperresponsive to IL-18 and overexpress the IL-18 receptor accessory chain. J Immunol 2001; 166:3757-62.
37. Oates JC, Ruiz P, Alexander A, Pippen AAM, Gilkeson GS. Effect of late modulation of nitric oxide production on murine lupus. Clin Immunol Immunopathol 1997; 83:86-92.
38. L-arginine. J Exp Med 1994; 179:651-60.
39. Farrel AJ, Blake DR, Palmer RM, Moncada S. Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis 1992; 51:1219-22.
40. Miesel R, Zuber M. Reactive nitrogen intermediates, and anti-nuclear antibodies and copper-threonine in serum of patients with rheumatic diseases. Rheumatol Int 1993; 12:95-102.
41. Belmont HM, Levartovshy D, Goel A et al. Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40:1810-6.
42. Gilkeson G, Cannon C, Oates J, Reilly C, Goldman D, Petri M. Correlation of serum measures of nitric oxide production with lupus disease activity. J Rheumatol 1999; 26:318-24.
43. Huang FP, Feng GJ, Lindop G, Stott DI, Liew FY. The role of interleukin 12 and nitric oxide in the development of spontaneous autoimmune disease in MRL/MP-lpr/lpr mice. J Exp Med 1996; 183:1447-59.